Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2014-05-19 Capital/Financing Update
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated May 19, 2014, for Cellectar Biosciences, Inc. It includes detailed information about the securities being registered, offering price, underwriting, risk factors, use of proceeds, capitalization, and other disclosures typical of a registration statement for an initial public offering or other securities offering. The presence of the SEC form type 'S-1' and the detailed prospectus content indicates this is a capital raising filing. This matches the definition of a Capital/Financing Update (CAP) which covers updates on company fundraising and financing activities. The document is not an annual report, earnings release, or other types of filings. Therefore, the correct classification is CAP with high confidence.
2014-05-19 English
FORM 10-Q
Interim / Quarterly Report Q1 2014
2014-05-14 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 5, 2014. It announces the receipt of orphan drug designation from the FDA for a diagnostic product. The document includes a press release as an exhibit. The content is a regulatory announcement about a specific event and does not contain financial statements, detailed financial data, or management discussion. It is not an earnings release, annual report, or interim report. The document is short (2831 characters) and primarily serves as a regulatory filing to disclose material information to the market. Therefore, it fits best under the category of Regulatory Filings (RNS).
2014-05-05 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 registration statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock incentive plans. It includes detailed information about the securities to be registered, the company's incorporation details, and provisions related to stock and governance. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2014-04-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2014, for Cellectar Biosciences, Inc. The content describes an announcement of the upcoming annual meeting of stockholders, including the date, location, agenda items such as election of directors, and the record date for stockholders entitled to vote. There is no detailed financial data, management discussion, or full report content. The document is an announcement of an event related to the Annual General Meeting but does not contain the AGM materials or the voting results. Given the short length (2552 characters) and the nature of the content, it is not an Annual Report, AGM Information, or Voting Results. It is a regulatory announcement about the AGM event, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2014-04-11 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content specifically announces a change in the company's CEO, Dr. Simon Pedder becoming President and CEO. There is no financial data or detailed report content, only a press release about management change. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is short and it is not a full financial report or earnings release. Therefore, the correct classification is MANG with high confidence.
2014-04-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.